NAPZIN Meglumine (Flunixin Meglumine Injection)

NAPZIN Meglumine Injection is an advanced, high-potency veterinary non-steroidal anti-inflammatory drug (NSAID) formulation meticulously engineered to alleviate acute inflammation, control visceral and musculoskeletal pain, and facilitate comprehensive clinical recovery in large animals and equines operating under rigorous professional veterinary care. Combining a concentrated dose of active flunixin meglumine within a specialized, sterile injectable vehicle, this professional-grade therapeutic preparation delivers targeted analgesic, anti-inflammatory, and anti-endotoxic support designed specifically for animals confronting acute colic, musculoskeletal lameness, soft-tissue inflammation, or complex systemic shock challenges. Because of its potent pharmacological profile and profound physiological impact, the administration of NAPZIN Meglumine Injection requires precise clinical diagnosis, individualized treatment planning, and strict adherence to professional veterinary guidelines.

What Is NAPZIN Meglumine?

NAPZIN Meglumine is a specialized veterinary therapeutic compound formulated for parenteral administration under professional clinical supervision.

INDICATIONS

In females at birth

• Prevents fever, pain, or discomfort in newly delivered females, promoting their speedy recovery and increased milk production from the mammary gland without inflammation.
• It reduces inflammation in the female reproductive tract, promoting improved blood circulation, tissue oxygenation, and the delivery of defense and repair blood cells. It improves colostrum secretion during the first 5 hours after application (postpartum), thanks to improved circulation and oxygenation of the mammary gland, as well as the proper delivery of oxytocin, secreted by the pituitary gland.

Bovines

• For the treatment of endotoxemia, acute or chronic respiratory diseases, acute mastitis and pododermatitis, as well as an adjuvant in down cow syndrome and in the control of infectious and/or mechanical diarrhea in calves.
• It is also indicated to relieve disorders associated with skeletal muscle and smooth muscle conditions.

Equines

• Indicated for inflammation and pain associated with musculoskeletal disorders (laminitis), in cases of endotoxemia and for the relief of visceral pain associated with colic, adjuvant in the treatment of colitis and acute respiratory disease.

Pigs

• For the treatment of fever, inflammation of the musculoskeletal system (lameness in general) and any type of pain.
• Prevents the signs and inflammation caused by damage that occurs during the birthing process within the sow’s reproductive tract, whether due to the natural delivery of piglets or dystocia.

DOSAGE AND ROUTES OF ADMINISTRATION

The general dose for all species is 1.1 to 2.2 mg/kg, administered intramuscularly (IM) or intravenously (IV) for a period of 12, 24 or 36 hours depending on severity.

Equines

• In cases of colic, laminitis: 1.1 mg/kg daily for 5 days only IV or IM
• As an anti-inflammatory and against endotoxemia 0.25 to 0.5 mg/kg IV.

In equines, the therapeutic response is observed between 15 to 60 minutes after intravenous administration.

Pigs

When to apply NAPZIN ® during the first 12 hours after delivery:

• Improves productive status by increasing performance.
• Improves milk production.
• Improves the weaning weight of the litter.

Routine application of NAPZIN® after farrowing will result in increased milk production in sows and:

• Improved weight gain in piglets (12 to 14 g per day).
• Reduction in mortality per litter (0.55 piglets per litter on average).
• Better piglet weight at weaning (more than 250 to 270 g)
• Best weight of small piglet (100 g at weaning)
• Improved litter weight at weaning (5.5 to 6.28 kg)

Small species

Dogs

In dogs the dose is 0.5 to 2.2 mg/kg IM or IV every 24 hours for a maximum of 2 days.

For eye diseases 0.5 mg/kg every 12 hours (1 to 2 treatments)

For surgical pain 1 mg/kg IV SCO IM

To control fever (pyrexia) 0.25mg/kg

Cats

In cats 0.25 mg/kg SC every 24 hours only repeat the treatment if necessary once more.

PRESENTATIONS: 100 ml, 250 ml

PHYSICAL AND CHEMICAL CHARACTERISTICS: It belongs to the group of non-steroidal anti-inflammatory drugs and is a substitute for nicotinic acid. It is unique in its chemical structure and is recommended to be stored between 2 and 30° C. It is characterized by its high degree of conjugation to plasma proteins. This situation explains the high concentration of the drug in inflammatory fluids due to the extravasation of proteins and fluids from the bloodstream and the acidic pH of the area of ​​inflammation.

NAPZIN® MECHANISM OF ACTION It acts by inhibiting the cyclooxygenase enzymes of the arachidonic acid cascade, suppressing the production of certain chemical mediators (histamine, proteolytic enzymes, etc.) that are involved in the inflammatory process, thus manifesting its analgesic, antipyretic, and anti-inflammatory properties. At low doses, it also reduces thromboxanes (TXs) and prostaglandins (PG12), decreasing signs of endotoxemia, making it an excellent alternative for equine colic.

PHARMACOKINETICS: Flunixin Meglumine is rapidly absorbed after parenteral administration. Its volume of distribution is 0.43 to 0.49 L/kg, and its half-life is 5.7 to 6.2 hours. Plasma levels are reached within 5 to 10 minutes after administration, so its effect is immediate. It is highly conjugated to plasma proteins, favoring its concentration in the area of ​​inflammation. It is excreted in feces, urine, and in very small amounts in milk.

USE DURING PREGNANCY, LACTATION OR LAY

Post-marketing studies in cattle have shown that use of the product within the first 36 hours after delivery leads to a higher incidence of retained placenta. The product should only be administered within the first 36 hours after delivery, after an appropriate evaluation by a veterinarian. Treated animals should be monitored to prevent cases of retained placenta.

Do not administer to pregnant mares or sows.

INTERACTIONS WITH OTHER MEDICINES

It is preferable not to administer NAPZIN to animals undergoing general anesthesia until they have fully recovered.

CONTRAINDICATIONS:

Do not use in animals suffering from heart, liver, or kidney disease, when there is a possibility of gastrointestinal ulceration or bleeding, or when there is evidence of blood dyscrasia. Do not use in animals suffering from colic caused by ileus and associated with dehydration. Do not use in animals suffering from chronic musculoskeletal disorders. Do not use in animals with known hypersensitivity to the active ingredient. Do not use in mares producing milk for human consumption. Do not administer to pregnant mares or sows. Do not use the product within 48 hours prior to the expected date of bovine farrowing. Do not administer to breeding sows, breeding pigs, and piglets weighing less than 6 kg.

OVERDOSE

Overdose is associated with gastrointestinal toxicity

WARNINGS

This product is for veterinary use only. Store in a cool place. Keep out of reach of children.

WITHDRAWAL PERIOD

In cattle, use the meat 24 hours after the last application and in milk 12 hours after the last application. In pigs, use the meat 21 days after the last application.

Active Ingredient and Formulation

• Active Components: Contains pharmaceutical-grade flunixin meglumine, a potent, non-narcotic, non-steroidal analgesic with cyclooxygenase (COX) inhibitory activity designed to suppress inflammatory pathways, reduce pyrexia (fever), and mitigate endotoxin-induced shock.

• Vehicle and Presentation: Formulated in a specialized, pharmaceutical-grade sterile aqueous injectable solution supplied in a secure multi-dose glass vial designed for controlled veterinary dispensing and administration in large animals.

What Is NAPZIN Meglumine Used For?

Primary Veterinary Indications

• Analgesic and Anti-Inflammatory Therapy: Routinely utilized by equine veterinarians and professional animal caretakers to alleviate visceral pain associated with acute equine colic, reducing the need for emergency surgical intervention when appropriately managed.

• Musculoskeletal Management: Formulated to assist animals experiencing acute inflammation, pain, and lameness associated with musculoskeletal disorders, soft-tissue injury, joint inflammation, and post-surgical recovery.

• Endotoxic Shock Support: Serves as a critical adjunct in managing acute systemic inflammation and endotoxemia associated with severe gastrointestinal disease or septic conditions under veterinary oversight.

Administration and Dosage Considerations

Route and Dosing

• Route of Administration: Administered via intravenous or deep intramuscular injection utilizing rigorous aseptic techniques to prevent localized tissue irritation or microbial contamination. Intravenous administration is preferred in acute colic settings for rapid onset of action.

• Veterinary Supervision: Exact dosage schedules, frequency of administration, and total treatment duration must be determined and monitored exclusively by a qualified equine veterinarian based on the individual animal’s body weight, clinical diagnosis, and metabolic status. Never guess or extrapolate dosages under any circumstances.

Important Safety Information

• Contraindications: Do not administer to animals with known hypersensitivity to flunixin meglumine, or to patients with pre-existing gastrointestinal ulceration, renal disease, hepatic impairment, or hypovolemic shock where renal perfusion is severely compromised. Avoid concurrent administration with other NSAIDs or corticosteroids.

• Side Effects: Prolonged or inappropriate administration can lead to gastrointestinal mucosal irritation, gastric or right dorsal colon ulceration, renal papillary necrosis, and localized tissue reaction if administered improperly into muscle tissue.

• Competition and Withdrawal: Administrators and trainers must thoroughly review current governing body regulations regarding prohibited substances and mandatory withdrawal times prior to competing performance animals, as NSAID metabolites remain detectable in biological samples.

• Professional Guidance: Due to its potent physiological properties, use must be strictly supervised by a licensed animal health professional to mitigate potential adverse systemic effects.

Storage and Handling

• Store at controlled room temperature, protected from direct sunlight, excessive heat, and freezing temperatures.

• Maintain strict aseptic technique when puncturing multi-dose glass vials to prevent microbial contamination during repeated use.

• Keep securely out of reach of children, unauthorized individuals, and animals at all times.

Frequently Asked Questions

What is NAPZIN Meglumine used for?

It is a professional veterinary NSAID injection utilized to alleviate acute visceral pain (such as colic), reduce musculoskeletal inflammation, control fever, and manage endotoxemic shock in large animals.

What is the active ingredient in NAPZIN?

It contains flunixin meglumine, a potent cyclooxygenase inhibitor with rapid analgesic and anti-inflammatory activity.

How is NAPZIN Meglumine administered?

It is administered via intravenous or deep intramuscular injection by or under the direct supervision of a qualified equine veterinarian.

Is veterinary supervision required for this product?

Yes, this compound is a potent prescription anti-inflammatory preparation requiring professional clinical diagnosis, careful patient monitoring, and strict compliance with veterinary guidance.

Can NAPZIN cause gastrointestinal side effects?

Yes, like all potent NSAIDs, excessive or prolonged dosing can induce gastrointestinal ulceration and renal compromise, making professional oversight essential.

Order NAPZIN Meglumine Online

NAPZIN Meglumine is available for order through our platform subject to veterinary prescription verification and full compliance with local regulatory requirements. Ensure that valid authorization and prescription documents are prepared prior to completing your checkout. For assistance regarding stock availability, secure ordering protocols, or delivery options, please contact our customer support team.